Disc Medicine to Host Webcast on Phase 3 EPP Drug Trial Results

Disc Medicine, Inc. (NASDAQ: IRON), a clinical-stage biopharmaceutical company based in Watertown, Mass., announced Friday it will hold a corporate webcast to present topline findings from its APOLLO Phase 3 clinical trial evaluating bitopertin as a treatment for erythropoietic protoporphyria, a rare and painful blood disorder.

The webcast is scheduled for Monday, October 19, 2026, at 8:00 a.m. Eastern Time. The company did not disclose the trial results in advance of the presentation, keeping investors and analysts in anticipation of data that could shape the regulatory and commercial trajectory of the experimental compound.

Read more Antheia Wins $80M Defense Dept. Funding for Drug Manufacturing →

Bitopertin is among the leading pipeline assets for Disc Medicine, which has concentrated its research efforts on serious hematologic diseases — conditions affecting the blood that often carry significant unmet medical need. Erythropoietic protoporphyria causes severe light sensitivity due to a buildup of protoporphyrin in red blood cells, and there are currently limited treatment options approved for the condition in the United States.

Phase 3 topline readouts are closely watched in the biotech sector because they represent the final stage of clinical evidence typically required before a company can seek regulatory approval from the Food and Drug Administration. A positive outcome from APOLLO could position Disc Medicine to advance bitopertin toward an FDA submission, while an unfavorable result would likely raise significant questions about the drug's future development path.

Continue reading at GlobeNewswire - Industry News on Financial Services.